MMMichael J. McNamara

Michael J. McNamara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael J. McNamara has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina P. Rodriguez

    Department of Medicine, Division of Medical Oncology, University of Washington, 825 Eastlake Ave E. MS G4-940, Seattle, WA, 98109, USA

    3 shared publications
  • Davendra Sohal

    Cleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA

    3 shared publications
  • David J. Adelstein

    Cleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA

    3 shared publications
  • Denise I. Ives

    Cleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA

    3 shared publications
  • Joanna W. Bodmann

    Cleveland Clinic, Taussig Cancer Institute, Hematology and Oncology, 9500 Euclid Avenue, R35, Cleveland, OH, 44195, USA

    3 shared publications
  • Lisa A. Rybicki

    Cleveland Clinic, Quantitative Health Sciences, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    3 shared publications

Latest Publications

  • Open Access

    Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

    by Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero, Brian Gastman

    Background Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. Methods We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months). Responses of injected (on-target) and uninjected (off-target) lesions were evaluated according to RECIST 2.0. Results The overall response rate for on-target lesions was 90%, with 6 patients experiencing a complete response in injected lesions. Two patients had off-target lesions, which were completely resolved after treatment. Blood samples were tested for 3 complete responders and 2 partial responders. CD4:CD8 ratio and frequencies of circulating PD1+ CD4 and CD8 T cells were elevated in complete responders but not partial responders. One patient died due to causes unrelated to melanoma and one patient died of progression of the disease. Conclusion Our data suggest that combining checkpoint inhibitor(s) with T-VEC injection may provide a synergistic efficacy for patients with unresectable melanoma. We observed a better overall response rate and complete response rate compared to published studies on similar therapeutic regimens.


  • Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

    by Michael J. McNamara, David J. Adelstein, Daniela S. Allende, Joanna W. Bodmann, Denise I. Ives, Sudish C. Murthy, Daniel Raymond, Siva Raja, Cristina P. Rodriguez, Davendra Sohal, et al.

    Preoperative therapy is frequently employed in the management of esophageal adenocarcinoma. However, many patients are found to have advanced pathologic stage and have poor outcomes. A prognostic factor which identifies this patient population before surgery would be desirable, as alternative treatment strategies may be warranted. Between 2/08 and 1/12, 60 evaluable patients with locally advanced esophageal adenocarcinoma enrolled in single-arm phase II trial of induction chemotherapy, surgery, and post-operative adjuvant chemo-radiotherapy (CRT). A clinical stage of T3, N1, or M1a (AJCC 6th) was required for eligibility. Induction chemotherapy with epirubicin 50 mg/m2 d1, oxaliplatin 130 mg/m2 d1, and fluorouracil 200 mg/m2/day continuous infusion for 3 weeks, was given every 21 days for 3 cycles and was followed by surgical resection. Adjuvant CRT consisted of 50–55 Gy @ 1.8–2.0 Gy/day and 2 cycles of cisplatin (20 mg/m2/day) and fluorouracil (1000 mg/m2/day) given as 96-h infusions during weeks 1 and 4 of radiotherapy. Dysphagia was assessed at baseline and after induction chemotherapy. Persistent dysphagia was associated with worse distant metastatic control [HR 3.48 (1.43–8.43), p = 0.006], recurrence free survival [HR 3.04 (1.34–6.92), p = 0.008], and overall survival [HR 3.31 (1.43–7.66), p = 0.005]. Persistent dysphagia was associated with more advanced pathologic T descriptor (pT) (p = 0.048) and N descriptor (pN) (p = 0.002), a greater median number of involved lymph nodes (3 v 1, p = 0.003), and greater residual tumor viability (p = 0.05). No patients with persistent dysphagia had pT0-T2 or pN0 disease. Persistent dysphagia after induction chemotherapy is associated with more advanced pathologic stage and inferior outcomes.

  • Open Access

    The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen

    by Michael J. McNamara, Lisa A. Rybicki, Davendra Sohal, Daniela S. Allende, Gregory M. M. Videtic, Cristina P. Rodriguez, Kevin L. Stephans, Sudish C. Murthy, Siva Raja, Daniel Raymond, et al.

    The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen


  • Open Access

    A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with Locoregionally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction

    by Michael J. McNamara, David J. Adelstein, Joanna W. Bodmann, John F. Greskovich, Denise I. Ives, David P. Mason, Sudish C. Murthy, Thomas W. Rice, Jerrold P. Saxton, Davendra Sohal, et al.


  • Current Developments in the Management of Locally Advanced Esophageal Cancer

    by Michael J. McNamara, David J. Adelstein

    Loco-regionally advanced esophageal cancer is a lethal disease with poor outcomes despite aggressive multimodality therapy. The appropriate management of these patients is contentious and no single standard of care has been defined. Literature suggests that preoperative chemoradiotherapy may be superior to preoperative chemotherapy. Recently, several developments have impacted the care of these patients. The 2010 AJCC TNM staging system now recognizes the biologic heterogeneity of the disease and stages adenocarcinoma and squamous cell carcinoma separately. Studies suggest potentially less toxic chemotherapeutic agents including oxaliplatin may be useful in the management of this disease. FDG-PET imaging appears to have prognostic value and may predict for pathologic response. In addition, several trials have explored inhibition of the ErbB1 (EGFR) and ErbB2 (Her2) receptors. The monoclonal antibody trastuzumab appears to extend survival for patients with metastatic gastric and gastroesophageal junction adenocarcinoma and is under investigation for use in patients with loco-regionally advanced disease.